Fusion Antibodies - Holding(s) in Company
Released
Released
Announcement PDF
RNS Number : 0444N
Fusion Antibodies PLC
15 May 2020
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft
Word format if possible)i
1a. Identity of the issuer or the underlying
issuer of existing shares to which voting
rights are attached ii:
FUSION ANTIBODIES PLC
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
X
Other (please specify)iii:
3. Details of person subject to the notification obligationiv
Name
AMATI AIM VCT PLC
City and country of registered office (if applicable)
London, UK
4. Full name of shareholder(s) (if different from 3.)v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed
or reached vi:
13/05/2020
6. Date on which issuer notified
(DD/MM/YYYY):
14/05/2020
7. Total positions of person(s) subject to the notification obligation
% of voting rights
attached to shares
(total of 8. A)
Resulting situation
5.52%
% of voting rights
through financial
instruments
(total of 8.B 1 + 8.B
2)
Total of both in %
(8.A + 8.B)
Total number of voting
5.52%
24,300,311
rights of issuervii
on the date on
which threshold
was crossed or
reached
Position of previous
notification (if
applicable)
6.07%
6.07%
8. Notified details of the resulting situation on the date on which the threshold was
crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)
Number of voting rightsix
% of voting rights
Indirect
Direct
(Art 9 of Directive
2004/109/EC) (DTR5.1)
GB00BDQZGK16
Direct
(Art 10 of Directive
2004/109/EC) (DTR5.2.1)
(Art 9 of Directive
2004/109/EC) (DTR5.1)
1,341,463
5.52%
1,341,463
SUBTOTAL 8. A
Indirect
(Art 10 of Directive
2004/109/EC) (DTR5.2.1)
5.52%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1
(a))
Type of financial
instrument
Expiration
datex
Exercise/
Conversion Periodxi
Number of voting rights
that may be acquired if
the instrument is
exercised/converted.
% of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of
Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of
financial
instrument
Expiration
date
x
Exercise/
Conversion
Physical or
cash
Period
settlement
xi
SUBTOTAL
8.B.2
xii
Number of
voting rights
% of voting rights
9. Information in relation to the person subject to the notification obligation (please mark
the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does
not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii
X
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal
entityxiv (please add additional rows as necessary)
Namexv
% of voting rights if
it equals or is higher
than the notifiable
threshold
% of voting rights
through financial
instruments if it
equals or is higher
than the notifiable
threshold
Total of both if it
equals or is higher
than the notifiable
threshold
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be
held
11. Additional informationxvi
Place of
completion
Date of
completion
Edinburgh UK
14/05/2020
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial
Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use
and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
HOLGPUWPAUPUUMA
Share your feedback
Discover